DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Wall Street expects a year-over-year increase in earnings on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2025. While this widely-known consensus outlook is ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

DexCom has a lower P/E than the aggregate P/E of 56.86 of the Health Care Equipment & Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also ...

DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

This was the stock's third consecutive day of losses.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks ...